Syndecan-4 as a Biomarker to Predict Clinical Outcome for Glioblastoma Multiforme Treated with WT1 Peptide Vaccine

Satoshi Takashima1 Department of Respiratory Medicine, Allergy & Rheumatic Diseases, Osaka University Graduate School of Medicine, 2-2 Yamadaoka, Suita City, Osaka565-0871, Japan

Yoshihiro Oka1 Department of Respiratory Medicine, Allergy & Rheumatic Diseases, Osaka University Graduate School of Medicine, 2-2 Yamadaoka, Suita City, Osaka565-0871, Japan;2 Department of Cancer Immunology, Osaka University Graduate School of Medicine, 1-7 Yamadaoka, Suita City, Osaka565-0871, Japan;3 Department of Immunopathology, Immunology Frontier Research Center (World Premier International Research Center), Osaka University, 3-1 Yamadaoka, Suita City, Osaka565-0871, Japan

Fumihiro Fujiki2 Department of Cancer Immunology, Osaka University Graduate School of Medicine, 1-7 Yamadaoka, Suita City, Osaka565-0871, Japan

Soyoko Morimoto2 Department of Cancer Immunology, Osaka University Graduate School of Medicine, 1-7 Yamadaoka, Suita City, Osaka565-0871, Japan

Hiroko Nakajima2 Department of Cancer Immunology, Osaka University Graduate School of Medicine, 1-7 Yamadaoka, Suita City, Osaka565-0871, Japan

Yoshiki Nakae1 Department of Respiratory Medicine, Allergy & Rheumatic Diseases, Osaka University Graduate School of Medicine, 2-2 Yamadaoka, Suita City, Osaka565-0871, Japan;4 Department of Hematology, Kitano Hospital, 2-4-10 Ohgimachi, Kita-ku, Osaka City, Osaka530-8480, Japan

Jun Nakata5 Department of Cancer Immunotherapy, Osaka University Graduate School of Medicine, 2-2 Yamadaoka, Suita City, Osaka565-0871, Japan

Sumiyuki Nishida1 Department of Respiratory Medicine, Allergy & Rheumatic Diseases, Osaka University Graduate School of Medicine, 2-2 Yamadaoka, Suita City, Osaka565-0871, Japan

Naoki Hosen6 Department of Cancer Stem Cell Biology, Osaka University Graduate School of Medicine, 1-7 Yamadaoka, Suita City, Osaka565-0871, Japan

Naoya Tatsumi5 Department of Cancer Immunotherapy, Osaka University Graduate School of Medicine, 2-2 Yamadaoka, Suita City, Osaka565-0871, Japan

Kenji Mizuguchi7 National Institutes of Biomedical Innovation, Health & Nutrition 7-6-8 Saito-Asagi, Ibaraki City, Osaka567-0085, Japan

Naoya Hashimoto8 Department of Neurosurgery, Kyoto Prefectural University Graduate Schoolof Medicine, 465 Kajii-cho, Hirokoji-agaru, Kawaramachi-dori, Kamigyo-ku, Kyoto City, Kyoto602-8566, Japan;9 Department of Neurosurgery, Graduate School of Medicine, Osaka University, 2-2 Yamadaoka, Suita City, Osaka565-0871, Japan

Yusuke Oji6 Department of Cancer Stem Cell Biology, Osaka University Graduate School of Medicine, 1-7 Yamadaoka, Suita City, Osaka565-0871, Japan

Akihiro Tsuboi5 Department of Cancer Immunotherapy, Osaka University Graduate School of Medicine, 2-2 Yamadaoka, Suita City, Osaka565-0871, Japan

Atsushi Kumanogoh1 Department of Respiratory Medicine, Allergy & Rheumatic Diseases, Osaka University Graduate School of Medicine, 2-2 Yamadaoka, Suita City, Osaka565-0871, Japan;3 Department of Immunopathology, Immunology Frontier Research Center (World Premier International Research Center), Osaka University, 3-1 Yamadaoka, Suita City, Osaka565-0871, Japan

Haruo Sugiyama2 Department of Cancer Immunology, Osaka University Graduate School of Medicine, 1-7 Yamadaoka, Suita City, Osaka565-0871, JapanCorrespondence[email protected]

show all

Syndecan-4 as a Biomarker to Predict Clinical Outcome for Glioblastoma Multiforme Treated with WT1 Peptide Vaccine

Articles from other publishers (15)

Information for

Open access

Opportunities

Help and information

Your download is now in progress and you may close this window

Login or register to access this feature

Syndecan-4 as a Biomarker to Predict Clinical Outcome for Glioblastoma Multiforme Treated with WT1 Peptide Vaccine

Citations (15)

Articles from other publishers (15)

Related research

To cite this article:

Download citation

Information for

Open access

Opportunities

Help and information

Keep up to date